Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update

Roni P. Dodiuk-Gad; Wen-Hung Chung; Laurence Valeyrie-Allanore; Neil H. Shear


Am J Clin Dermatol. 2015;16(6):475-493. 

In This Article

4 Assessment and Treatment of SJS/TEN

SJS/TEN is one of the few dermatological diseases that constitute a true medical emergency. Early recognition and prompt appropriate management can be lifesaving. Nevertheless, there are no internationally accepted management guidelines. The following represents the authors' protocol for assessment (Table 2) and treatment (Table 3) of patients with SJS/TEN, based on the most up-to-date literature and abundant experience in treating patients with SJS/TEN. We hope these suggested guidelines may serve as a practical clinical tool for physicians in the management of patients with SJS/TEN. While this is international by definition, it is not necessarily a consensus-based protocol. For the readers' convenience, we have designed two tables: the assessment protocol (Table 2) and the treatment protocol (Table 3), which summarize the key elements.

4.1 Assessment

Assessment is conducted by the simple method of ''5Ds by Dr. Shear''. Specifically, these are Diagnosis, Drug exposure, Differential diagnosis, Determining the probabilities of causality, and Determining the severity of SJS/TEN.

4.1.1 Diagnosis. The physician must determine whether the patient's clinical symptoms are signs of SJS/TEN or of another skin disease. The diagnosis is based on three key clinical elements: cutaneous and mucous membrane manifestations, systemic involvement, and histological findings. A thorough history and a comprehensive physical examination are essential for accurate diagnosis of SJS/TEN. Basically, the classic manifestation of SJS/TEN consists of initial signs of ''flu-like'' symptoms (malaise, fever, anorexia) in the prodromal phase, followed by cutaneous and mucous membrane inflammation and pain (ocular, oral, and genital) and other systemic involvement (see elaboration in Sect. 3).

For cutaneous assessment, the classification of SJS/TEN defined by Bastuji-Garin et al.[69] includes the proper definition of the characteristic skin lesions. For BSA involvement, the Wallace rule of nines can be used; a value of 9 % of BSA is given for involvement of the head, each arm, the chest, and the abdomen; 18 % is given for each leg and the back; and 1 % is given for the groin. Also, the patient's palm can serve as a reference point roughly equivalent to 1 % of BSA for total assessment. For children and infants, the Lund and Browder chart is used to assess the burned BSA. The extent of epidermal detachment should also be assessed. It should be emphasized that only necrotic skin that is already detached (e.g. blisters, erosions) or detachable skin (a positive Nikolsky sign, whereby slight rubbing of the skin results in exfoliation of the outermost layer) should be included in the evaluation of the extent of epidermal detachment.[61]

Histological assessment is a key element in the diagnosis of SJS/TEN and to rule out diseases that may mimic SJS/TEN. Characteristic histological features include extensive keratinocyte destruction with separation of the epidermis from the dermis at the dermoepidermal junction.[95] A skin biopsy for direct immunofluorescence (DIF) from perilesional skin should also be conducted for the differential diagnosis. Blood work and consultation with specialists (ophthalmology, otolaryngology, and gynecology) for comprehensive assessment of mucous membrane involvement are to be conducted in the primary assessment of the patient, according to the clinical signs. During hospitalization, ocular assessment should be conducted on a daily basis, and consultation with other specialists is based on the patient's clinical signs and symptoms.

A rapid immunochromatographic test for serum granulysin was found to be useful for the prediction of SJS/TEN[96] and, in the future, it may serve as a clinical tool for early diagnosis. However, it is still not known if granulysin may also be useful as a prognostic marker for SJS/TEN.

4.1.2 Drug Exposure (Timing). All medications, regardless of the route of administration, must be considered, especially new drugs taken in the 8 weeks prior to the skin reaction. Drugs taken intermittently, such as vitamins, sedatives, pain relievers, laxatives, and natural products, must also be considered. It is also important to avoid a common mistake, which is to falsely implicate drugs that were introduced for early symptoms of SJS/TEN, such as antipyretics or antibiotics, in the causality of SJS/TEN. Assessment of the lag period—the time between initiation of the drug and the onset of the cutaneous reaction—is crucial in view of the different lag times for different cutaneous drug reactions. A recommended method for drug exposure analysis is to chart a timeline of the patient's illness in order to visualize the chronology and facilitate comprehension of the event. The timeline includes the relevant information (the starting day, dosage, and discontinuing day) for each drug and the signs and symptoms throughout the period in question.[97,98] In SJS/TEN, the lag period is 4–28 days. The median latency was found to be longer ( >30 weeks) for drugs with no associated risk.[65]

4.1.3 Differential Diagnosis. Establishing a differential diagnosis that takes into account all possible diagnoses is essential. Ranking of the approximate likelihood of each condition is encouraged. The major differential diagnoses for SJS/TEN are detailed in Table 2. The following clues may assist in differentiating them.

Staphylococcal Scalded Skin Syndrome (SSSS): In addition to the different clinical findings (typically the lack of mucous membrane involvement in SSSS), performing a frozen section to evaluate the level of epidermal separation, which is intra-epidermal in SSSS but sub-epidermal in TEN, is a quick tool for differentiating between these diseases.[99]

Generalized Bullous Fixed Drug Eruption (GBFDE): The following typical clinical features of GBFDE may aid in differentiating it from SJS/TEN: (1) blistering usually affects only a small percentage of BSA, and between the large blisters there are sizable areas of intact skin; (2) erosive mucosal involvement is rare and, when it does occur, is rather mild; (3) patients usually do not feel sick or have fever, and generally they are in much better overall health than those with SJS/TEN; (4) most patients report a history of a similar, often local reaction.[99]

Acute Graft-Versus-Host Reaction (aGVHR): aGVHR is a multi-organ disease process (major organs include the skin, liver, and gastrointestinal tract) resulting from interactions of donor-derived T cells against antigens expressed on the cells of the recipient host. Severe cases of aGVHR present with symptoms similar to those of SJS/TEN (clinical and histological): diffuse erythroderma, desquamation, bullae, a positive Nikolsky sign, and ulcerations of mucous membranes. Histologically, grade IV aGVHR involves full-thickness epidermal necrosis and has histological findings identical to those in SJS/TEN. The clinical setting assists in differentiation of aGVHR from SJS/TEN. aGVHR occurs in patients with bone marrow and allogeneic hematopoietic stem cell transplants, usually 2 weeks post-transplantation.[100]

TEN-Like Lupus Erythematosus or Lupus-Associated TEN (TEN-Like LE): This was first described in 2003.[101] It is a subacute or acute cutaneous rash, followed by bullous lesions and epidermal cleavage. It has been reported to occur in patients with established systemic lupus erythematosus, and it is considered to result from aggressive inflammatory epidermal basal layer damage due to increased extension of the interface dermatitis characteristic of lupus erythematosus. In distinction to SJS/TEN, there is a lack of an apparent trigger and an absence of systemic and mucous membrane involvement.[102]

4.1.4 Determining the Probabilities of Causality by the Suspected Drugs. Drug exposure is the most common cause of SJS/TEN,[61] with more than 200 culprit drugs identified.[3] The groups of medications associated with a high risk of inducing SJS/TEN vary according to the population (Table 4). Nonmedication triggers, implicated mainly in SJS, include infections, contrast media, and vaccinations.[59,103,104] The most significant challenge in assessing SJS/TEN is determining the probabilities of causality between the suspected drugs and the untoward clinical event.

The following methods are helpful:

Patient History: The lag period (the time between initiation of the drug and the onset of the cutaneous reaction) and personal and familial previous cutaneous reactions to drugs are crucial factors in assessing likelihoods.[97]

Analysis of the Literature: Search for information regarding the frequency with which the type of reaction is related to a particular drug (PubMed at; Litt's Drug Eruptions and Reactions Manual and database at

Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN): This is an algorithm for the assessment of drug causality in SJS/TEN, developed by the RegiSCAR Study Group, and consists of six parameters according to which the drug causality is classified as very unlikely, unlikely, possible, probable, or very probable.[105]

Adjunctive Laboratory Assessments: In this decade, there has been a successful translation of the laboratorybased discovery of the HLA alleles associated with severe cutaneous adverse reactions to drugs to a clinical guidelinebased test.[25] These tests are best utilized as genetic screening tools prior to drug prescription. However, they may also serve as a simple, fast, safe, and reliable method of establishing clear causality between a drug and a disease in cases of SJS/TEN (but should never be used in isolation as a single test in causality assessment) and are an important tool in counseling both the patient and his/her family members about drug avoidance.[106] The HLAs are specific to a drug and an ethnic background[107] (see elaboration in Sect. 2 and Table 1). In vitro assessments such as the lymphocyte transformation test (LTT)[108] and granulysin expression[109] have been reported. However, caution should always be exercised regarding false positive and false negative results. In addition, at this point in time, no laboratory tests should be used as justification for rechallenge when SJS/TEN associated with a drug is clinically possible.

4.1.5 Determining the Severity. The severity of SJS/TEN depends mostly on the haemodynamic status and the extent of systemic involvement, determined by epidermal barrier breakdown symptoms such as hypothermia, dehydration, secondary infection, and organ involvement induced by necrosis of epithelial lining, such as respiratory distress syndrome, colitis, hepatitis, and nephritis (see elaboration in Sect. 3).[110] This assessment is conducted by taking a thorough history, a physical examination, blood work, and proper imaging (a chest X-ray is advised for all patients; further imaging is based upon clinical findings).

The following clinical and histological findings were found to be validated values for determination of severity.

SCORTEN: This scoring system was developed to stratify the severity of illness and predict mortality in patients with TEN. To optimize the predictive value of this tool, SCORTEN is to be performed on days 1 and 3 post-admission (see elaboration in Sect. 3 and Table 2).[85]

Histological Findings: In a retrospective analysis of the clinical records and histological material from 37 patients with TEN, the extent of dermal mononuclear inflammation was found to predict the clinical outcome approximately as well as SCORTEN. Increased inflammation correlated with a worse prognosis; a mean dermal mononuclear cell count >215 cells per high-power field in patients with 30 % or more total BSA sloughing predicted a worse prognosis (65 % mortality), compared with 24 % mortality in those with<215 cells per high-power field.[95] However, in a retrospective study analyzing clinical records and skin biopsies from 108 patients with SJS, SJS/TEN overlap, and TEN, dermal infiltrate severity was not associated with day 1 SCORTEN or hospital death, but full-thickness epidermal necrosis was associated with mortality.[111]

Early Withdrawal and Half-Life of the Causative Drug: A 10-year observational study including 113 patients with TEN or SJS found that the earlier the causative drug was withdrawn, the better the prognosis was (odds ratio 0.69 for each day; 95 % confidence interval 0.53–0.89). Patients exposed to causative drugs with long half-lives had an increased risk of dying (odds ratio 4.9; 95 % confidence interval 1.3–18.9).[84]

4.2 Treatment

The treatment of SJS/TEN consists of a multidisciplinary approach, which includes the following important aspects (Table 3):

4.2.1 Identification and Withdrawal of the Culprit Drug. The medication history during the previous 2 months is documented and all suspected and non-essential medications are withdrawn.[99]

4.2.2 Transfer of the Patient to an Appropriate Unit. The patient is transferred to intensive care, a burn unit, or another specialty unit.[112,113]

4.2.3 Supportive Care. Thermoregulation: Cutaneous thermoregulation is impaired by the compromised skin barrier; thus, increasing the room temperature to 28–32 _C is important, especially for patients with large amounts of epidermal detachment.[99,114]

Airway Protection: The decision to intubate and ventilate is made on the basis of the following considerations: the extent of upper airway mucosal involvement, potential for airway obstruction, severity of respiratory distress, and anticipated analgesia and sedation requirements.

Fluid Replacement and Assessment of Fluid Balance: Fluid management differs from that of patients with burn injuries; fluid and electrolyte requirements are less than for burns of the same extent.[115] Fluid replacement with electrolyte solution (0.7 mL/kg/% affected area) and albumin solution (5 % human albumin, 1 mL/kg/% affected area) is advised.[99] The goal is to maintain a urinary output of 0.5–1 mL/kg/h.[115]

Nutritional Support: Enteral nutritional hypercaloric and high-protein diet support is advised to prevent protein loss and promote healing. Enteral nutrition through a nasogastric tube should be considered in patients unable to ingest food. Nasogastric feeding should be initiated cautiously because of possible gastrointestinal involvement and potential difficulties in placing a tube in the presence of oropharyngeal involvement.[116] Parenteral nutrition is not recommended, because it is commonly poor tolerated and is associated with an increased risk of sepsis.[114] Patients with SJS/TEN require fewer calories per day than patients with burns. A recommended equation for the estimation of energy requirements in pediatric SJS/TEN patients is (24.6 × weight in kg) + (% wound × 4.1) + 940.[117] Other guidelines advise the following protocol for nutrition through a gastric tube: 1500 calories in 1500 mL over the first 24 h, increasing by 500 calories daily to 3500–4000 calories daily.[99]

Pain Management: Management of pain is a major point, often underestimated, and necessitates assessment and medical treatment accordingly. Use of morphine should be considered, with appropriate respiratory monitoring. If available, patient-controlled analgesia is advised.[114] Placement of the patient on an alternating pressure air mattress may also reduce the pain.[99]

Venous Thromboembolism Prophylaxis: Standard prophylactic anticoagulation therapy is advised for patients who are bedridden.[114]

Monitoring for Infection: Antibiotic prophylaxis is not recommended. However, monitoring for infection is mandatory, and if clinical suspicion arises, bacterial cultures should be obtained from the skin, urine, and blood, and empirical treatment with antibiotics given until culture results are available.[99] Some guidelines advise performing bacterial and fungal cultures from the skin, urine, and blood on a regular basis (2–3 times per week).[112–114]

Psychological Support: Professional psychological support for the patient and family members is important.[99]

4.2.4 Medical Treatment. Systemic Immunomodulatory Treatment in Adults: The optimal therapeutic regimen has yet to be established, but, according to recent publications, the following conclusions can be drawn.

  1. Intravenous immunoglobulin (IVIg): Use of IVIg does not yield survival benefits in adults with SJS/TEN.[118–120]

  2. Cyclosporine: In an open-label, phase II trial to determine the safety and possible benefit of cyclosporine, cyclosporine was found to decrease the death rate and the progression of detachment in adults (dosage: 3 mg/kg/day for 10 days and tapered over a month).[121] Other publications have also reported beneficial use of cyclosporine in SJS/TEN.[122,123]

  3. Systemic Corticosteroids: These were associated with clinical benefit according to the EuroSCAR (European Study of Severe Cutaneous Adverse Reactions) study[124] and were reported to be the most common treatment for SJS/TEN in a recent survey of 50 drug hypersensitivity experts from 20 countries.[125] One of the suggested protocols is intravenous dexamethasone 1.5 mg/kg pulse therapy (given for 30–60 min) for three consecutive days.[126]

  4. TNF Inhibitors: Treatment with anti-TNF biologic agents seems to be very promising for the management of SJS/TEN.[127,128] In a recent study in ten consecutive patients with TEN, 50 mg of etanercept was administered in a single subcutaneous injection. All patients responded promptly to treatment, reaching complete re-epithelialization without complications or side effects.[129] In addition, the preliminary results of a prospective, randomized, open-label trial currently underway in Taiwan,[125] comparing etanercept with systemic corticosteroids in patients with SJS/TEN, demonstrated that the average time to reach maximal skin detachment and complete skin healing was shorter in the etanercept group. Also, in vitro investigations demonstrated that etanercept, corticosteroids, and thalidomide significantly decreased granulysin expression of blister cells. Etanercept did not, however, increase the cytotoxic effect on keratinocytes found with thalidomide.[125]

Systemic Immunomodulatory Treatment in Children: The bulk of the literature on the management of SJS/TEN includes adults, and these findings may not be simply extrapolated to children. On the basis of the scant quality literature in children, both IVIg and systemic corticosteroids seem to improve the outcome of children with SJS/TEN.[130–132]

Skin Treatment: There are no clinical guidelines for the skin care of patients with SJS/TEN. Debridement of the necrotic epidermis was recommended in past publications.[112,133] Recent publications advise avoiding debridement (which may cause hypertrophic scars) and recommend considering the detached epidermis as a natural biological dressing that favors re-epithelialization.[64,114,125] Various topical treatments that have been reported include bioactive skin substitutes, semi-synthetic and synthetic dressings, and topical antimicrobials.[112,133] A recent report on the management of SJS/TEN in an experienced French referral center described the following treatment: wound care once daily with minimal manipulation to prevent skin detachment, including a bath containing a solution of chlorhexidine 1/5000 (morphine is given prior to the bath and/or an equimolar mix of oxygen and nitrogen monoxide during the bath); if bathing is not possible, the chlorhexidine solution is sprayed 2–3 times daily on the skin; blister fluid is aspirated while maintaining the blister roof; petrolatum is systematically applied over all detached skin areas; topical sulfa-containing medications are avoided; and hydrocellular or absorbent nonadhesive dressings are applied at least once daily to cover pressure points.[114] Another recently published protocol[134] based the wound management algorithm on the stage of denudation and skin loss, categorizing four stages of skin with specialized treatments accordingly.

Mucous Membrane Treatment: Specialized care is essential to prevent lifelong complications.[64]

  1. Ocular management: Although there is no standardized care for ocular management, the following supportive local treatment is advised: tear replacement solutions; removal of peudomembranes; lysis of symblepharon; debridement of loosened epithelium; topical antibiotics to prevent secondary infection; topical corticosteroids to prevent scar formation; and cycloplegic drops to relieve pain, photophobia, and ciliary spasm.[135] Amniotic membrane transplantation has been found to be effective in the acute and chronic stages of SJS/TEN.[136,137] A ''Triple-TEN'' protocol for severe ocular cases was recently reported,[138] comprising the following:

    1. Subconjunctival triamcinolone (Kenalog™ 20 mg) is administered into each of the fornices to curb the local inflammatory response without compromising systemic immunity.

    2. Amniotic membrane tissue mounted on a polycarbonate skirt (ProKera®) is placed over the corneal and limbal regions to facilitate reepithelialization of the ocular surface.

    3. A steeply curved acrylic scleral shell spacer (Technovent, SC21) is inserted to vault each lid away from the globe and provide a barrier to symblephara formation. This treatment offers an effective therapeutic option without the need for microsurgical equipment, a microscope, or sutures in the critical care setting.

  2. Oropharyngeal Management: The mouth should be rinsed several times daily with an antiseptic or antifungal solution, and the lips should be lubricated with an ointment such as dexpanthenol.[99]

  3. Genital Management: Vulvovaginal sequelae of SJS/TEN are well documented in the literature, though little consensus exists about effective preventive strategies. The goals of therapy should be to protect vaginal function by decreasing adhesion formation and agglutination, as well as limiting vulvovaginal adenosis with potentially neoplastic changes in affected tissue.[72,139–141] Some treatment protocols suggest wet dressings or sitz baths and lubrication with emollient to avoid adhesions and strictures of genital erosions in females.[99,114] In a recent expert opinion publication,[141] the authors advised using the following protocol:

    1. Early initiation of intravaginal steroids: Betamethasone valerate 0.1 % cream applied every 12 h to the vulva externally, and betamethasone valerate 0.1 % ointment applied every 12 h to the internal vaginal mucosa via a Milex® dilator (Milex Products Inc., Chicago, IL, USA); regular application of antifungal creams as well. Treatment was advised to be given in alternating courses to prevent tachyphylaxis (for example, 3 days on, 4 days off), and treatment with topical steroids should be continued until resolution of the acute phase of the illness.

    2. Vaginal molds: In addition to topical steroids, a soft vaginal mold should be placed prophylactically as early as possible during the acute phase of the illness and used regularly until complete healing of ulcerative lesions has occurred. The mold can be coated with topical steroids, and patients are advised to wear it for most of the day, removing it only for cleansing, medication application, and toileting. The author advised using Milex_ vaginal dilators; they are made of latex-free, hypoallergenic silicone and come in various lengths and widths. They are available to purchase from online distributors (e.g. CooperSurgical, Trumbull, CT, USA). Special consideration is to be given to virginal patients, in whom use of vaginal molds would be inadvisable. Instead, the steroid formulation can be applied via a standard vaginal applicator. Also, use of a dilator is not advised in the pediatric population, to prevent physical discomfort and emotional trauma.

    3. Menstrual suppression: To decrease the risk of vaginal adenosis, menstrual suppression in the acute phase and healing process is advised. Detailed information on treatment of confirmed adenosis and the importance of close colposcopic surveillance, given the association of this process with subsequent malignancy, is described in this report.[141]

Special Considerations in Pregnant Women: Many cases of SJS/TEN occurring during pregnancy have been reported, with high survival rates of both the mothers and the newborns.[142–144]

The following major aspects are of special concern when treating a pregnant woman with SJS/TEN:

  1. Fetal status: Fetal stress due to maternal disease may lead to premature labor.

  2. Delivery methods: Although vaginal deliveries have been reported,[145] Caesarean section has been used in many cases[142,144] because of genital mucous membrane involvement of TEN. Risk management for labor includes frequent obstetric examinations to assess possible vaginal strictures, which may impair spontaneous delivery. If a spontaneous delivery is planned, preparations for a Caesarean section should be made, and anesthetic and neonatology support should be available.[142]

  3. Involvement of the disease within the fetus/newborn: SJS/TEN may develop during pregnancy in the mother alone or simultaneously in the mother and fetus; it can be lethal for the fetus.[142] In cases reported in the literature, most babies presented as healthy.[142,144] However, a few cases of TEN in newborns, including one case of simultaneous TEN in a mother and her stillborn fetus, have been reported.[143]

  4. HIV: Pregnancy increases the chances of developing SJS 14-fold in HIV-infected pregnant women treated with nevirapine.[146] A recently published retrospective study of patients admitted to a university hospital with SJS/TEN over a 3-year period in Cape Town, South Africa,[147] found that nevirapine-based antiretroviral therapy—a regimen for women in the first trimester of pregnancy and those planning a pregnancy to prevent mother-to-child transmission of HIV infection—placed pregnant women at a disproportionally higher risk of developing SJS/TEN.

Avoiding High-Risk Drugs and Monitoring for Secondary Cutaneous Adverse Drug Reactions: Avoiding high-risk drugs (Table 4) is important, as SJS/TEN predisposes the patient to developing additional cutaneous adverse drug reactions.

Monitoring and Treating Acute Complications: The most common cause of death in SJS/TEN in the acute stage is septicemia. Nonetheless, other possible complications induced by changes in the hemodynamic status and systemic involvement of SJS/TEN are to be monitored and treated.

4.2.5 Communication with the Patient, Family, Health Care Providers and Regulatory Agencies. Patient and Family: Good communication strategies will aid in the interactions with the patient and family following SJS/TEN and will decrease the likelihood of lawsuits. Physicians are advised to follow these steps:

  1. Express empathy and say ''sorry'' according to the ''apology laws'' in an honest and respectful fashion, and in a way that protects the physician from having an apology used against him in case of legal action. See

  2. Provide disclosure in a ''disclosure meeting'' planned according to the acronym CONES (Context: arrange the setting for a quiet, uninterrupted meeting, and decide on the participants; Opening shot: the first sentence in the meeting explains the aim of the conversation; Narrative: lay out the facts, and avoid using the words ''error'' and ''mistake'', since the SJS/TEN is a result of multiple factors, particularly when the facts are not completely known; Emotions: provide an empathic environment; Summary).

  3. Provide the patient with clear information about SJS/TEN and its cause, the name of the offending drug, potential cross-reacting drugs, and drugs that can be safely taken as an alternative to the offending drug. In addition, provide the results of the HLA genetic screening, if conducted, and advise the patient to wear a MedicAlert® bracelet.

  4. Family counseling is part of the management plan because of genetic predisposition. The authors' protocol is to advise all first-degree family members to avoid use of the drug that caused the SJS/TEN in their family member (unless past treatment was safe),[3] and to provide information on HLA genetic screening for the relevant drug if available.

Health Care Providers: Information on the adverse event must be provided to the family physician and entered into the patient's records.

Regulatory Agencies: Report the cutaneous adverse drug reaction to the manufacturer and regulatory agencies.[148] International reporting systems include MedWatch, the FDA Safety Information and Adverse Event Reporting Program (, and the WHO Uppsala Monitoring Centre (UMC;

4.2.6 Prior to Discharge. Information on the Culprit Drug: This should be provided to the patient and their primary physicians. Appropriate labeling should be applied to the medical record, according to the most likely causative drugs. Care should be taken to verify that the appropriate coding has been applied (e.g. International Classification of Diseases, Tenth Revision [ICD-10] for future reference and studies.

Medical Recommendations: Advise on medical treatment, if still necessary, and provide clear recommendations on sun protection to prevent post-inflammatory hyperpigmentation.

Explanation of the Possible Long-Term Medical Complications and Information on Medical Follow-Up: Longterm physical complications of patients surviving SJS/TEN are common (see elaboration in Sect. 3). Hence, it is highly important to explain to the patient the prognosis and the need for follow-up.

Offering Emotional Support: We recommend using the General Health Questionnaire-12 (GHQ-12)[149]—the most commonly used screening instrument for psychiatric disorders in various settings—as a quick and valid screening instrument for psychological distress. Patients should be asked to complete the scale at discharge, and scores of 2 or greater should trigger a referral to a psychiatrist or psychologist.[94]

Referral to a Support Group: Several support groups have been established in different countries, such as the Stevens–Johnson Syndrome Foundation in the USA, CAST (Canadians Against Stevens Johnson Syndrome & Toxic Epidermal Necrolysis) in Canada, and Amalyste in France. More information on support groups in different countries can be found at